Spero Therapeutics, Inc. (SPRO)
Chart Events
Performance Outlook
| Previous Close | 0.8274 |
| Open | 0.7800 |
| Bid | 0.7670 x 1200 |
| Ask | 0.7678 x 900 |
| Day's Range | 0.7550 - 0.8354 |
| 52 Week Range | 0.7320 - 19.8700 |
| Volume | |
| Avg. Volume | 768,393 |
| Market Cap | 25.401M |
| Beta (5Y Monthly) | 1.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.2550 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SPRO
Related Research
- Spero Therapeutics, Inc.Technical Assessment: Bearish in the Intermediate-TermMonday provided a much-needed rest for the stock market after a very large rebound last week. Following that strong week (and we've seen this before during the current decline), the "bottom-callers" are out, but not in big numbers. That's probably a good thing, as others are calling this another bear-market rally. From a technical perspective and using our own interpretation, it is far too early to call the bottom as there is just not enough of the needed evidence.RatingFair ValueEconomic Moat7 days agoArgus Research
- Reuters
UPDATE 1-U.S. FDA declines to approve Spero's urinary tract infection drug
The U.S. Food and Drug Administration (FDA) declined to approve Spero Therapeutics Inc's oral antibiotic drug for the treatment of patients with complicated urinary tract infections, the company said on Monday. In the complete response letter, the health regulator concluded that Spero's late-stage study testing the drug was insufficient and an additional study would be required, the drugmaker said. Spero had sought approval for its most advanced drug candidate, tebipenem, to treat the infections, including a type of kidney inflammation called pyelonephritis in adult patients with limited oral treatment options.
- GlobeNewswire
Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis. The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022. In th
- Skift
History of Short-Term Rentals Filled With Arrogance and Missed Opportunities
Looking back at the history of short-term rentals coming online starting in the mid-1990s, it’s easy to see how arrogant thinking and missed opportunities left their mark, and swayed the sector’s trajectory. That’s an easy takeaway from Skift’s recently published three-part Definitive Oral History of Short-Term Rentals because this theme of opportunities seized and lost […]
